There are several adverse events that can occur in the setting of tumor necrosis factor-α inhibitor treatment for inflammatory bowel disease. The most common side effects include infection and malignancy. There are however several less frequent adverse events that can be classified as dermatologic, neurologic, cardiac, and hepatic. The aim of this review was to assist clinicians to recognize and manage these infrequent adverse events that occur during use of tumor necrosis factor-α antagonists.
Article first published online 26 February 2016.
*Icahn School of Medicine at Mount Sinai, New York, NY;
†Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; and
‡Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, ON, Canada.
Reprints: Neeraj Narula, MD, FRCPC, McMaster University Medical Centre, Health Sciences Centre, Room 3V3, 3rd Floor 1280 Main Street West, Hamilton, ON, Canada L8S 4K1 (e-mail: email@example.com).
J.-F. Colombel has served as consultant, advisory board member or speaker for AbbVie, Amgen, Bristol Meyers Squibb, Celltrion, Ferring, Genentech, Giuliani SPA, Given Imaging, Janssen, Merck & Co., Millenium Pharmaceuticals Inc., Nutrition Science Partners Ltd., Pfizer Inc. Prometheus Laboratories, Receptos, Sanofi, Schering Plough Corporation, Takeda, Teva Pharmaceuticals, UCB Pharma, Vertex, Dr. August Wolff GmbH & Co. The remaining authors have no conflict of interest to disclose.
This article does not contain any studies with human or animal subjects performed by any of the authors.
Received October 23, 2015
Accepted November 17, 2015